Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T19:05:42.606Z.
Calculation as of: 2026-10-06T19:05:42.606Z.
Quote observation: 2026-10-06T19:05:10.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Market Cap
$749.48M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$758.10M
Free Cash Flow Yield
6.97%
TTM Avg
7.62%
3Y Avg
7.21%
5Y Avg
5.53%
Market Cap
$735.63M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$729.39M
Free Cash Flow Yield
N/A
TTM Avg
23.05%
3Y Avg
23.09%
5Y Avg
23.09%
Market Cap
$768.95M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$778.22M
Free Cash Flow Yield
N/A
TTM Avg
6.80%
3Y Avg
7.30%
5Y Avg
6.57%
Market Cap
$779.56M
Free Cash Flow Yield
N/A
TTM Avg
46.69%
3Y Avg
46.69%
5Y Avg
28.31%
Market Cap
$719.10M
Free Cash Flow Yield
N/A
TTM Avg
5.55%
3Y Avg
5.46%
5Y Avg
5.46%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apnimed, Inc. (APMD) | $756.64M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $749.48M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $758.10M | 6.97% | 7.62% | 7.21% | 5.53% |
| Candel Therapeutics, Inc. (CADL)vs › | $735.63M | N/A | N/A | N/A | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $729.39M | N/A | 23.05% | 23.09% | 23.09% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $768.95M | N/A | N/A | N/A | N/A |
| Varex Imaging Corporation (VREX)vs › | $778.22M | N/A | 6.80% | 7.30% | 6.57% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $779.56M | N/A | 46.69% | 46.69% | 28.31% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $719.10M | N/A | 5.55% | 5.46% | 5.46% |
| Geron Corporation (GERN)vs › | $782.66M | N/A | 1.71% | 1.71% | 1.71% |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
